The NHS has announced that it will fast-track patients with advanced head and neck cancers in England into a clinical trial ...

Global non-profit organisation DEBRA Research and Queen Mary University of London have entered into a partnership aimed at advancing drug development for epidermolysis bullosa (EB).

This statistic highlights the increasing importance of technology in healthcare and underscores the need to balance clinical responsibilities with the growing technological demands on providers. For ...

Let’s be honest, ‘client service’ is one of the most lifeless phrases in our industry. It confines people to their accounts and frames relationships as ...

The US Food and Drug Administration (FDA) has granted accelerated approval to Jazz Pharmaceuticals’ Modeyso (dordaviprone) as ...

AbbVie and Genmab’s epcoritamab has shown promise as part of a combination treatment for relapsed or refractory follicular ...

Empathy is a core capability, regardless of function – our ability to connect with others and understand how information is ...

In a crowded oncology market, strategy-led storytelling, analytics-driven design, and sustainability-centered innovation are ...

ASCO® 2025 wasn’t only about oncology breakthroughs - it was also a showcase for how technology is redefining congress ...

This year’s ASCO® meeting spotlighted a bold shift in oncology: the possibility of curing metastatic disease. A new trial ...

Johnson & Johnson (J&J) has announced that it is seeking US Food and Drug Administration (FDA) approval to include new ...

Sanofi’s investigational multiple myeloma (MM) therapy has been granted orphan drug designation by the US Food and Drug Administration (FDA) to treat patients with relapsed or refractory disease.